October 5, 2026- InspiroGene™ by McKesson announced the publication of its third annual 2026 Cell and Gene Therapy Report: Building the Bridge from Breakthrough Science to Commercial Patient Access.
The 2026 report is InspiroGene’s most expansive yet, combining provider research across oncology, rheumatology and ophthalmology, with payer perspectives, patient and advocate insights, pipeline analysis and expert discussion on how technology and artificial intelligence can help address persistent access barriers.
The report draws on InspiroGene by McKesson’s 2026 primary research with 200 U.S. physicians, as well as interviews with 35 payer leaders representing approximately 295 million covered lives, an analysis of the late-stage U.S. CGT pipeline, and perspectives from patients, advocates and leading industry experts.
Key Findings in the 2026 Report Include:
- Oncology adoption keeps growing, but access barriers persist
- New specialties are optimistic, but want stronger data and evidence
- Physicians from different specialties have opposing views on where care will be centered in the future
- Payers are standardizing cell therapy reimbursement faster than gene therapy reimbursement
- AI could help close a persistent access gap
- Patients still face real-world barriers that data alone can’t capture
- Access to cell and gene therapy continues to expand gradually
The full 2026 Cell and Gene Therapy Report can be found at www.inspirogene.com/cgt-report.